Home 
Find my MSL
Vaccine Stability Calculator
REPORT SUSPECTED ADVERSE REACTIONS 
Pipeline
At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines.
Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval.
DISEASE STATES
mRNA COVID-19 2nd Gen vaccine candidate GSK4396687*
Safety and immunogenicity against SARS-CoV-2 in seropositive adults 18 years of age and older
mRNA COVID-19 2nd Gen vaccine candidate GSK4396687*
Safety and immune response in healthy adults
Cytomegalovirus (CMV) vaccine candidate GSK3993129*
Safety, reactogenicity, and immunogenicity in healthy adults 18 to 50 years of age
iNTS (Invasive non-typhoidal salmonella prophylaxis) vaccine candidate GSK4077164*
Safety, reactogenicity, and immunogenicity in European (Stage 1) and African (Stage 2) adults 18–50 years of age
MenABCWY 2nd Generation Vaccine Candidate GSK4023393*
Safety, effectiveness, and immunogenicity in healthy adolescents and adults 10 to 50 years of age
MenABCWY 2nd Generation Vaccine Candidate GSK4023393*
Safety, tolerability, and immune response in healthy infants 2 months of age at enrollment
Meningococcal Group B Vaccine GSK3536829*
Safety and immunogenicity of Bexsero when administered concomitantly with MenACWY conjugate vaccine (Menveo) to healthy infants (V72_56)
Safety and immunogenicity of 13-valent pneumococcal vaccine and Bexsero when administered together with routine infant vaccines in healthy infants (V72_57)
mRNA Influenza vaccine candidate GSK4382276*
Safety and immunogenicity in healthy adults 18-55 and 65 years and older
Safety, reactogenicity, and immunogenicity in healthy adults 18-45 years and 60-80 years of age
mRNA Influenza vaccine candidate GSK4382276*
Reactogenicity, safety, and immunogenicity in healthy adults aged 18-50 years (Phase 1) and 18-85 years of age (Phase 2)
Pandemic mRNA H5 Influenza vaccine candidate GSK5536522*
Safety, reactogenicity, and immunogenicity, dose-finding and dose-confirmation of the flu pandemic mRNA vaccine against pandemic H5N1 in healthy adults 18–85 years
mRNA Influenza vaccine candidate GSK4382276*
Safety and immunogenicity in adults 18 years of age and older
S. pneumoniae vaccine candidate GSK5101956*
Safety, tolerability and immunogenicity in a dose-escalation study in toddlers 12 to 15 months of age
S. pneumoniae vaccine candidate GSK5101956*
Safety, tolerability and immunogenicity of 3 different doses compared with PCV13 in healthy infants
Salmonella Typhoid/Paratyphoid A Vaccine Candidate GSK3536867*
Safety in adults 18 to 50 years of age
Shigella vaccine candidate GSK3536852*
Assess efficacy, safety, and immunogenicity in healthy adults 18 to 50 years of age
Varicella New Strain vaccine candidate GSK4178116*
Immune response and safety in healthy children 12 to 15 months of age
Varicella New Strain vaccine candidate GSK4178116*
Immune response and safety when given as a second dose to healthy children (12–15 months of age) 3 months after given a first dose
Respiratory Syncytial Virus Vaccine, Adjuvanted
Immunogenicity and safety in adults 18 years and older with lung or kidney transplant compared to healthy adults
Respiratory Syncytial Virus Vaccine, Adjuvanted
Extension and crossover study to evaluate immunogenicity and safety of different revaccination schedules and persistence of a single dose in adults 60 years and older
Immunogenicity in adults 18-49 years old at increased risk for RSV-LRTD compared to adults 60 years and older
Measles, Mumps, Rubella, Varicella New Strain Vaccine Candidate GSK4406371
Immunogenicity and safety in children 4 to 6 years of age
Malaria (Plasmodium falciparum, Next Generation)
Safety, efficacy and immunogenicity in children aged 5 to 17 months
mRNA Seasonal Flu/COVID-19 vaccine candidate GSK5475152*
Reactogenicity, safety, and immune response in adults age 18 years and older
UPEC adjuvanted recombinant subunit vaccine candidate GSK5102188
Safety, reactogenicity, and immune response in adults afted 18–64 years (Part 1) and preliminary efficacy in females 18–64 years (Part 2)
0 results - Use filter to search Pipeline
Disclaimer
This document contains information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for both approved and investigational compounds.
Some agents are approved in select indications. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov.
Footnotes
*In-license or other alliance relationship with third party.
